Pediatrics

Genglycos wins accelerated approval to cut daily cornstarch reliance in patients aged 8 and older with the rare metabolic disorder.

As case counts rise in the current outbreak, pharmacists must be prepared to counsel patients regarding management, including pediatric patients who require unique considerations.

Findings published in Lancet Child & Adolescent Health arrive as a new US executive order shifts rotavirus vaccination to shared clinical decision-making.

Adding family-based behavioral treatment to standard care nearly doubled clinically meaningful weight loss in kids in the TEAM UP trial.

The findings point to persistent vaccine hesitancy and access gaps in the years since the COVID-19 pandemic, with authors calling for stronger clinician recommendations and school-based vaccination sites.

A study finds low-income and minority families are likely among those experiencing consequences from reduced measles, mumps, rubella, and varicella (MMRV) vaccine uptake amid the worst surge in US measles cases in decades.

The FDA expanded Wilate's approval for routine prophylaxis to reduce bleeding episodes in children younger than 6 years with von Willebrand disease, supported by phase 3 WIL-33 data showing low annualized bleeding rates and favorable tolerability.

The FDA clears roflumilast, a PDE4 inhibitor, for once-daily steroid-free plaque psoriasis care in kids ages 2+.

The approval adds a 55-mg prefilled syringe for weight-based dosing and makes risankizumab the first IL-23 inhibitor cleared for pediatric patients weighing less than 40 kg.

The new indication is for patients aged 12 and older with unresectable or metastatic SS who received prior chemotherapy and are positive for various genetic subtypes.

With this approval, Capvaxive is the only PCV specifically indicated and studied in the US for use in this patient population.

A new Lancet study provides the first plausible evidence that a national package of food labeling, marketing restrictions, and school food policies can reduce excess weight among young children.

The integrated CGM is now indicated for individuals 2 years and older who do not use insulin.

What began as a modest survey has grown into one of the most trusted barometers of frontline pharmaceutical expertise in the country.

Afrezza is the only ultra rapid-acting inhaled insulin approved by the FDA to improve glycemic control in children, adolescent, and adult patients with diabetes.

FDA approves benralizumab for hypereosinophilic syndrome, driven by NATRON phase 3 clinical trial data showing fewer flares and improved fatigue.

Newborn vitamin K shot refusals rise, boosting bleeding risk; learn neonatal safety facts and how the vitamin K shot prevents deadly VKDB.

This approval marks the first high-efficacy B-cell depletion therapy approved for pediatric patients 10 years and older.

A new study describes the high symptom burden carried by pediatric long COVID patients and highlights integrative medicine's role in their care.

FDA expands teplizumab to age 1 year for stage 2 type 1 diabetes—pharmacists must learn dosing, infusion logistics, and safety monitoring.

Delaying hepatitis B vaccination beyond birth increases preventable infections, liver cancer deaths, and costs.

Symptom-based dosing reduced time to medical readiness for discharge compared with scheduled opioid, without increasing short-term safety risks.

The treatment's approval was supported by positive evidence from the phase 1/2 CHORD clinical trial.

New Yale University research offers reassurance for pregnant patients and their clinicians, although evidence of lasting structural damage remains a concern.

Dupilumab becomes the first biologic approved for children aged 2 to 11 years with uncontrolled chronic spontaneous urticaria, marking a significant expansion in treatment options and pharmacist-led care considerations.